Literature DB >> 22354379

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.

Aurélie Goyenvalle1, Jordan Wright, Arran Babbs, Vivienne Wilkins, Luis Garcia, Kay E Davies.   

Abstract

Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disorder caused by mutations in the dystrophin gene. Antisense-mediated exon skipping is one of the most promising approaches for the treatment of DMD but still faces personalized medicine challenges as different mutations found in DMD patients require skipping of different exons. However, 70% of DMD patients harbor dystrophin gene deletions in a mutation-rich area or "hot-spot" in the central genomic region. In this study, we have developed 11 different U7 small-nuclear RNA, to shuttle antisense sequences designed to mask key elements involved in the splicing of exons 45 to 55. We demonstrate that these constructs induce efficient exon skipping both in vitro in DMD patients' myoblasts and in vivo in human DMD (hDMD) mice and that they can be combined into a single vector to achieve a multi skipping of at least 3 exons. These very encouraging results provide proof of principle that efficient multiexon-skipping can be achieved using adeno-associated viral (AAV) vectors encoding multiple U7 small-nuclear RNAs (U7snRNAs), offering therefore very promising tools for clinical treatment of DMD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22354379      PMCID: PMC3369406          DOI: 10.1038/mt.2012.26

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  53 in total

1.  Accurate quantification of dystrophin mRNA and exon skipping levels in duchenne muscular dystrophy.

Authors:  Pietro Spitali; Hans Heemskerk; Rolf H A M Vossen; Alessandra Ferlini; Johan T den Dunnen; Peter A C 't Hoen; Annemieke Aartsma-Rus
Journal:  Lab Invest       Date:  2010-05-10       Impact factor: 5.662

2.  Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy.

Authors:  Zejing Wang; James M Allen; Stanley R Riddell; Paul Gregorevic; Rainer Storb; Stephen J Tapscott; Jeffrey S Chamberlain; Christian S Kuhr
Journal:  Hum Gene Ther       Date:  2007-01       Impact factor: 5.695

3.  Internal deletion compromises the stability of dystrophin.

Authors:  Davin M Henderson; Joseph J Belanto; Bin Li; Hanke Heun-Johnson; James M Ervasti
Journal:  Hum Mol Genet       Date:  2011-05-10       Impact factor: 6.150

4.  Exon-skipped dystrophins for treatment of Duchenne muscular dystrophy: mass spectrometry mapping of most exons and cooperative domain designs based on single molecule mechanics.

Authors:  Christine Carag Krieger; Nishant Bhasin; Manorama Tewari; Andre E X Brown; Daniel Safer; H Lee Sweeney; Dennis E Discher
Journal:  Cytoskeleton (Hoboken)       Date:  2010-11-10

Review 5.  The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein.

Authors:  D Schümperli; R S Pillai
Journal:  Cell Mol Life Sci       Date:  2004-10       Impact factor: 9.261

6.  Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.

Authors:  Haiyan Jiang; Linda B Couto; Susannah Patarroyo-White; Tongyao Liu; Dea Nagy; Joseph A Vargas; Shangzhen Zhou; Ciaran D Scallan; Jurg Sommer; Sharmila Vijay; Federico Mingozzi; Katherine A High; Glenn F Pierce
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

7.  Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.

Authors:  Aurélie Goyenvalle; Arran Babbs; Gert-Jan B van Ommen; Luis Garcia; Kay E Davies
Journal:  Mol Ther       Date:  2009-05-19       Impact factor: 11.454

8.  The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.

Authors:  M Koenig; A H Beggs; M Moyer; S Scherpf; K Heindrich; T Bettecken; G Meng; C R Müller; M Lindlöf; H Kaariainen; A de la Chapellet; A Kiuru; M L Savontaus; H Gilgenkrantz; D Récan; J Chelly; J C Kaplan; A E Covone; N Archidiacono; G Romeo; S Liechti-Gailati; V Schneider; S Braga; H Moser; B T Darras; P Murphy; U Francke; J D Chen; G Morgan; M Denton; C R Greenberg; K Wrogemann; L A Blonden; M B van Paassen; G J van Ommen; L M Kunkel
Journal:  Am J Hum Genet       Date:  1989-10       Impact factor: 11.025

Review 9.  Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.

Authors:  Annemieke Aartsma-Rus; Ivo Fokkema; Jan Verschuuren; Ieke Ginjaar; Judith van Deutekom; Gert-Jan van Ommen; Johan T den Dunnen
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

10.  Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy.

Authors:  Aurélie Goyenvalle; Kay E Davies
Journal:  Skelet Muscle       Date:  2011-02-09       Impact factor: 4.912

View more
  20 in total

1.  Localizing the RPGR protein along the cilium: a new method to determine efficacies to treat RPGR mutations.

Authors:  R Da Costa; E Glaus; A Tiwari; B Kloeckener-Gruissem; W Berger; J Neidhardt
Journal:  Gene Ther       Date:  2015-01-29       Impact factor: 5.250

2.  Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45.

Authors:  Andrew R Findlay; Nicolas Wein; Yuuki Kaminoh; Laura E Taylor; Diane M Dunn; Jerry R Mendell; Wendy M King; Alan Pestronk; Julaine M Florence; Katherine D Mathews; Richard S Finkel; Kathryn J Swoboda; Michael T Howard; John W Day; Craig McDonald; Aurélie Nicolas; Elisabeth Le Rumeur; Robert B Weiss; Kevin M Flanigan
Journal:  Ann Neurol       Date:  2015-03-02       Impact factor: 10.422

3.  AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy.

Authors:  Maëva Le Hir; Aurélie Goyenvalle; Cécile Peccate; Guillaume Précigout; Kay E Davies; Thomas Voit; Luis Garcia; Stéphanie Lorain
Journal:  Mol Ther       Date:  2013-06-11       Impact factor: 11.454

4.  Activating internal ribosome entry to treat Duchenne muscular dystrophy.

Authors:  Shireen R Lamandé; Kathryn N North
Journal:  Nat Med       Date:  2014-09       Impact factor: 53.440

Review 5.  State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications.

Authors:  Dan Wang; Guangping Gao
Journal:  Discov Med       Date:  2014-09       Impact factor: 2.970

6.  Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.

Authors:  Aurélie Goyenvalle; Arran Babbs; Jordan Wright; Vivienne Wilkins; Dave Powell; Luis Garcia; Kay E Davies
Journal:  Hum Mol Genet       Date:  2012-03-02       Impact factor: 6.150

Review 7.  Molecular and cell-based therapies for muscle degenerations: a road under construction.

Authors:  Emanuele Berardi; Daniela Annibali; Marco Cassano; Stefania Crippa; Maurilio Sampaolesi
Journal:  Front Physiol       Date:  2014-04-08       Impact factor: 4.566

Review 8.  Targeting Splicing in the Treatment of Human Disease.

Authors:  Marc Suñé-Pou; Silvia Prieto-Sánchez; Sofía Boyero-Corral; Cristina Moreno-Castro; Younes El Yousfi; Josep Mª Suñé-Negre; Cristina Hernández-Munain; Carlos Suñé
Journal:  Genes (Basel)       Date:  2017-02-24       Impact factor: 4.096

9.  Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice.

Authors:  Christina Gedicke-Hornung; Verena Behrens-Gawlik; Silke Reischmann; Birgit Geertz; Doreen Stimpel; Florian Weinberger; Saskia Schlossarek; Guillaume Précigout; Ingke Braren; Thomas Eschenhagen; Giulia Mearini; Stéphanie Lorain; Thomas Voit; Patrick A Dreyfus; Luis Garcia; Lucie Carrier
Journal:  EMBO Mol Med       Date:  2013-05-29       Impact factor: 12.137

Review 10.  Splicing therapy for neuromuscular disease.

Authors:  Andrew G L Douglas; Matthew J A Wood
Journal:  Mol Cell Neurosci       Date:  2013-04-28       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.